argenx SE
ARGXArgenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.
Drugs in Pipeline
16
Phase 3 Programs
9
Upcoming Catalysts
6
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
9 upcoming, 7 past
How ARGX's past catalysts played out
EFG PH20 SC
Active Idiopathic Inflammatory Myopathy
Empasiprubart IV
Chronic Inflammatory Demyelinating Polyneuropathy
IVIG (Intravenous Immunoglobulin)
Multifocal Motor Neuropathy (MMN)
Efgartigimod
Postural Orthostatic Tachycardia Syndrome
efgartigimod administration
Myasthaenia Gravis
empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy
Efgartigimod IV
Generalized Myasthenia Gravis
ARGX-113
Pemphigus Vulgaris
Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Cusatuzumab
Leukemia, Myeloid, Acute
efgartigimod PH20 SC in stage B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ARGX-119
Amyotrophic Lateral Sclerosis
ARGX-117
Multifocal Motor Neuropathy
ARGX-119 IV
Spinal Muscular Atrophy (SMA)
ARGX-110
Leukemia, Myeloid, Acute
Efgartigimod Alfa
Optic Neuritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy | - | - |
Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) | - | - |
Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
efgartigimod administration | Phase 3 | Myasthaenia Gravis | - | - |
empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis | - | - |
ARGX-113 | Phase 3 | Pemphigus Vulgaris | - | - |
Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
Cusatuzumab | Phase 2 | Leukemia, Myeloid, Acute | - | - |
efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ARGX-117 | Phase 2 | Multifocal Motor Neuropathy | - | - |
ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) | - | - |
ARGX-110 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Efgartigimod Alfa | Phase 2 | Optic Neuritis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in argenx SE's drug pipeline?→
CatalystAlert tracks 16 drug candidates in argenx SE's (ARGX) pipeline across Phase 3, Phase 2. Its lead program is EFG PH20 SC (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is argenx SE's next FDA catalyst?→
argenx SE's (ARGX) next tracked catalyst is a Phase 2 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARGX biotech catalysts?→
Add ARGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow argenx SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.